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TO THE EDITORCoronary Occlusion and
Ischemia ReductionI read with great interest the article by Jang et al. (1)
and the accompanying editorial by Barbato and
Wijns (2) regarding the long-term survival beneﬁt of
revascularization compared with medical therapy in
patients with coronary chronic total occlusion and
well-developed collateral circulation. According to
the authors, it seems as though all patients received
“modern medical therapy,” and because this was a
retrospective study, there was no requirement for
informed consent.
I congratulate the authors for a very nice piece of
work, but I would like to remind them that the term
they use (CTO), standing for chronic “total” occlu-
sion, might instead be abbreviated CCO, standing for
chronic coronary occlusion. “Total” is redundant
because all occlusions are total.
Several years ago, I wrote an article on coronary
artery collaterals (3). Before and since writing that
article, I have always believed that collaterals do not
appear angiographically unless ischemia is present in
the distribution of those collaterals. I have also never
believed that if the collateral provides excellent blood
ﬂow to the ischemic zone, ischemia will disappear
and the collaterals will remain. To put it somewhat
differently, in my opinion, visible collaterals only
exist if ischemia is present, and if ischemia is present,
the myocardium supplied by the collateral vessel is
viable.
All collateral seen angiographically may be pro-
tective against or limit infarction but may not provide
adequate ﬂow to prevent myocardial ischemia and
regional myocardial dysfunction. Thus, I do not
believe that all angiographically visible collaterals
eliminate myocardial ischemia, but they may make
ischemia more difﬁcult to provoke.
I could not ﬁnd out whether or not the patients
evaluated in this paper (1) had post-percutaneous
coronary intervention (PCI) angiography to deter-
mine the presence or absence of collaterals after the
revascularization was accomplished. This would have
been an important observation that would indicatethat collaterals are only present when the demand
(ischemia) for them is present.
The conclusion that the authors make, that
“aggressive revascularization by surgery or PCI
may reduce the risk of mortality and MACE [major
adverse cardiac events] by eliminating ‘ischemia’,”
seems reasonable to me, but I would also propose that
the risk of mortality and MACE may be reduced
if “ischemia” is eliminated by aggressive medical
therapy. In fact, I cannot think of a single incidence in
which the continued presence of ischemia is good for
the patient.*C. Richard Conti, MD
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3. Conti CR. Coronary artery collaterals. Clin Cardiol 2010;33:188–9.REPLY: Coronary Occlusion andIschemia ReductionMy colleagues and I appreciated the comments of
Professor Conti regarding the clinical signiﬁcance of
revascularization for the treatment of coronary
chronic total occlusion (CTO) with well-developed
collateral circulation. We read with interest the
editorial comment provided by Barbato and Wijns (1)
in addition to the letter to the editor by Conti. It is an
undeniable fact that successful revascularization of
CTO is associated with a survival beneﬁt, but the
greatest challenge of this aggressive CTO treatment is
the low predictability of successful revascularization
and the relatively high possibility of fatal complica-
tions. In this sense, we agree with Barbato and Wijns’
opinion that accurate risk stratiﬁcation and better
selection criteria for patients undergoing CTO
